Xencor Inc., a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, has appointed Bart Cornelissen as senior vice president and chief financial officer.   “Bart’s exceptional track record in financial planning and analysis, business development and organizational excellence will be of great value to Xencor as we advance our maturing clinical-stage pipeline of drug candidates and continue to explore our XmAb platforms ...